A team of biologists, data scientists, and engineers developing mechanical biomarkers to improve human health. The novel microfluidic platform allows to probe individual cells to quantify the mechanical signatures of disease. They are applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes and reduces treatment cost.
Reflecting their technology/biology hybrid company, at San Francisco office the data team sits across from a wet lab, and biologists handle python as well as pipettes. They believe close collaboration helps move fast to bring health insights to patients and their healthcare providers.
